Chemomab Therapeutics Advances Nebokitug for PSC Treatment

Chemomab Therapeutics Ltd. ( (CMMB) ) has released its Q1 earnings. Here is a breakdown of the information Chemomab Therapeutics Ltd. presented to its investors.

Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company focused on developing innovative treatments for fibro-inflammatory diseases, particularly targeting the soluble protein CCL24. The company is advancing its lead product, nebokitug, which has shown potential in treating primary sclerosing cholangitis (PSC) and systemic sclerosis.

In its first quarter of 2025, Chemomab Therapeutics reported significant progress in its clinical trials and regulatory pathway for nebokitug. The company announced positive 48-week data from its Phase 2 SPRING trial, which demonstrated improvements in key biomarkers for PSC patients. Additionally, Chemomab has aligned with the FDA on a streamlined regulatory approval process for nebokitug, potentially making it the first FDA-approved treatment for PSC.

Key financial highlights from the quarter include a net loss of $3.3 million, a decrease from the previous year’s first quarter loss of $3.9 million. Research and development expenses were reduced to $2.5 million, reflecting the winding down of Phase 2 trial activities. The company’s cash position stood at $10.6 million, with a runway extending to the second quarter of 2026.

Strategically, Chemomab is exploring multiple partnering options to advance the nebokitug program and is in discussions with potential partners to support its Phase 3 trial. The company is focused on leveraging its recent achievements to further its mission of addressing high unmet medical needs in fibro-inflammatory diseases.

Looking ahead, Chemomab remains committed to progressing nebokitug towards regulatory approval and exploring strategic collaborations to enhance its development pipeline. The company aims to continue building on its recent successes to bring innovative therapies to patients with severe fibro-inflammatory conditions.